Background: Coculture of mesenchymal stem cells (MSCs) from the retropatellar fat pad and peripheral blood has been shown to stimulate anterior cruciate ligament (ACL) fibroblast proliferation and collagen production in vitro. Current techniques of bioenhanced ACL repair in animal studies involve adding a biologic scaffold, in this case an extracellular matrix-based scaffold saturated with autologous whole blood, to a simple suture repair of the ligament. Whether the enrichment of whole blood with MSCs would further improve the in vivo results of bioenhanced ACL repair was investigated.
Tearing of the anterior cruciate ligament (ACL) is one of the more common knee ligament injuries, with an especially high prevalence in active adolescent athletes. 36 The current standard treatment is surgical restoration of the mechanical stability of the knee joint by replacing the torn ACL with a tendon graft; however, recent reports of increased failure rates in adolescents, 51 and the high rate of progression to premature osteoarthritis, 1 have stimulated interest in alternative treatments of this injury, including bioenhanced ACL repair. Bioenhanced ACL repair involves augmenting a suture repair of a ligament with placement of an extracellular matrix scaffold containing a biologic additive in the ligament wound site to stimulate ligament healing. This method, using whole blood or platelet-rich plasma as the biologic additive, has recently demonstrated reasonable results when evaluated in a large animal model of ACL injury. 30, 48 In these models, while the use of a scaffold alone has been found to be ineffective at improving the mechanics of a suture repair, 14 the combination of the scaffold and platelets (in the form of either platelet-rich plasma or whole blood) has been found to significantly improve the mechanical properties of a suture
The American Journal of Sports Medicine, Vol. 43 repair of the ACL 22 as well as the mechanical properties of an ACL graft. 15 The healing of the injured ACL using bioenhanced repair is primarily achieved by fibroblasts, which migrate from the ACL into the wound site. 34 Once fibroblasts are within the wound site, key processes including cell proliferation and collagen production result in the formation of a fibrovascular scar, which then remodels into tissue with a structure closer to that of the normal ligament. [32] [33] [34] [35] A recent in vitro study demonstrated that adding mesenchymal stem cells (MSCs) obtained from the adipose tissue or peripheral blood stimulated cellular proliferation and collagen production by ACL cells, 40 and thus we hypothesized that the stimulation of these behaviors with MSCs may lead to improved healing in vivo.
Other investigators 11, 25 have looked at the utility of adipose tissue-derived stem cells (ADSCs) for ligament engineering. These investigators found that human ADSCs could be pushed toward a ligament fibroblast phenotype by culturing them on a ligament-derived extracellular matrix scaffold, 25 although not by culture with epidermal growth factor (EGF) or basic fibroblast growth factor (bFGF). 11 Coculture of ACL fibroblasts and ADSCs led to an upregulation of collagen type I and type III gene expression not only in ACL fibroblasts but also in ADSCs when tested in vitro, 40 a further indication that these cells have the potential to modulate the behavior of surrounding cells through secretion of cytokines 4 as well as to differentiate down the fibroblast differentiation pathway. 11 ADSCs have also been found to be helpful for regenerating periodontal tissue when combined with platelets and studied in vitro 42 and in small animal models when combined with a poly(lactide-co-glycolide) (PLGA) scaffold. 2 These positive effects of MSCs in vivo may also be a result of MSCs functioning to suppress both transient and perpetual immune surveillance systems and creating an ideal healing environment by secreting factors and altering the local microenvironment. 3 Peripheral blood mononuclear cells have become a topic of recent interest as a potential source of MSCs. A comparison of peripheral blood mononuclear cell-derived stem cells (PBSCs) and bone marrow-derived MSCs demonstrated similar ability for self-renewal and trilineage differentiation of the 2 cell sources. 8 In a study using coculture of ACL fibroblasts and PBSCs, PBSCs had increased collagen type I gene expression, an indicator of their potential to differentiate into the fibroblast lineage. 40 PBSCs have also been shown to enhance the anabolic effects of platelet-rich plasma on ACL fibroblasts 53 as well as stimulate the proliferation and collagen gene expression in these cells by coculture. 40 The current method of using either ADSCs or PBSCs involves obtaining the cells, expanding them in culture, and then surgically reimplanting them. This series of procedures, while technically possible, represents significant health care costs and regulatory hurdles. The regulatory pathway for these biologic additives requires not only addressing all of the standard concerns of sterility and biocompatibility for biologics but also addressing the issues of exposure of the cells to potentially hazardous materials during processing (bacteria, bovine serum, other infectious agents), sterility at the time of implantation, and rigorous tracking of the identification of each sample throughout the culture process. Because of the additional costs and risks for the patient, particularly for diseases that are typically not life-threatening, these types of biologic additives need strong evidence of efficacy in preclinical models before any translation to clinical trials should be attempted.
Our central hypothesis was that the enrichment of whole blood with autologous ADSCs or PBSCs to the extracellular matrix scaffold for bioenhanced ACL repairs would enhance the biomechanical outcomes of the repair in the pig.
MATERIALS AND METHODS

Experimental Design
Approvals from the Institutional Animal Care and Use Committee were obtained before the start of this study. Based on an a priori sample size calculation, 24 male Yucatan mini-pigs in late adolescence with closed femoral and tibial physes (mean 6 SD: age, 20.2 6 2.25 months; weight, 56.9 6 8.3 kg) were randomized to 1 of 3 experimental groups ( Figure 1 ): (1) bioenhanced ACL repair using a bioactive scaffold with autologous whole blood (referred to as the ''Blood'' group), (2) bioenhanced ACL repair using the same bioactive scaffold with autologous whole blood and the addition of autologous ADSCs from the retropatellar fat pad (ADSC group), and (3) bioenhanced ACL repair using the same bioactive scaffold with autologous whole blood and the addition of autologous PBSCs (PBSC group). All animals were housed for 15 weeks after surgery.
Retropatellar ADSCs
The ADSCs were harvested as previously described. 40 Two weeks ahead of the ACL surgery, animals from the ADSC group had a small portion of their retropatellar fat pad from the left knee (mean weight, 1.1 6 0.21 g) removed through a small medial arthrotomy. This tissue was minced, digested with collagenase (Worthington Biochemical), and filtered through a cell strainer (BD Falcon). Cells were resuspended in growth medium (Dulbecco's modified Eagle's medium and Ham's F-12, 50/50 medium [Mediatech], 10% fetal calf serum [FCS; Sigma], 0.2 mM L-glutamine [Sigma], 100 IU/mL penicillin, and 100 mg/mL streptomycin [Sigma] ) and seeded at a density of 3 3 10 5 /cm 2 in a 150-cm 2 cell culture flask (Greiner Bio-One). Non-plastic adherent cells were taken off after 48 hours, and adherent cells were washed twice with phosphate-buffered saline (PBS) and expanded (Figure 1B ).
PBSCs
The PBSCs were isolated as previously described. 49 Two weeks before ACL repair, the animals from group PBSC ( Figure 1D ) had 50 mL of blood taken from the external jugular vein, which was placed on Percoll-Paque (1.077 g/mL; GE Healthcare Biosciences) and centrifuged. The cells from the lymphocyte/monocyte layer of the Percoll-Paque density gradient were resuspended in growth medium and seeded at a density of 3 3 10 6 /cm 2 in a 150-cm 2 cell culture flask. Non-plastic adherent cells were taken off after 48 hours, and adherent cells were washed twice with PBS and expanded ( Figure 1D ).
Fluorescent Labeling of ADSCs and PBSCs With Lentiviral Vector and Fluorescence-Activated Cell Sorting
The ADSCs and PBSCs were infected with a lentiviral vector containing the DNA of yellow fluorescent protein (YFP), which stably integrated the YFP gene into the cell DNA. Three days after labeling, fluorescence-activated cell sorting (FACS) was performed using FACSAria (BD Biosciences) to obtain 100% YFP expressing cell lines. Cells were then resuspended in growth medium and seeded at a density of 3 3 10 6 /cm 2 for further expansion. Third-passage cells were used for transplantation during the bioenhanced ACL repair procedure. Cultures of labeled cells were kept for 15 weeks to control for YFP expression. Determination of cell densities was conducted using a Cellometer Auto T4 Cell Counter (Nexcelom Bioscience).
Preparation of the Extracellular Matrix Scaffold
The extracellular matrix scaffolds (MIACH ACL Scaffold; Boston Children's Hospital) were aseptically manufactured as previously described. 31 Bovine fascia was solubilized by use of pepsin, and the resulting extracellular matrix digest was lyophilized in molds to create a cylindrical scaffold that was able to absorb 3 mL of autologous whole blood or 3 mL of autologous whole blood with added autologous ADSCs or PBSCs. The scaffold itself was nonautologous. 15 Scaffolds were stored at room temperature until surgery.
Determination of Scaffold Pore Size
Six scaffolds were cut transversely at variable locations. Cut surfaces were recorded by use of a Keyence VHX 2000 Digital Microscope (Keyence). Image J software (National Institutes of Health) was used to determine the average of 10 pores per slice.
Bioenhanced ACL Repair Procedure
To expose the ACL, the fat pad was partially resected (mean weight of resected fat pad, 6.6 6 2.2 g) through a medial arthrotomy. The ACL was cut between the proximal and middle thirds using a scalpel. All knees had the same level of gross anteroposterior (AP) instability after complete ACL transection as verified by joint subluxation with manual Lachman testing. Subsequently, the bioenhanced ACL repair was performed as previously described. 31 Briefly, a button loaded with 3 suture loops was fixed to the lateral distal femur. The scaffold was threaded onto 2 of the sutures and slid up into the femoral notch next to the femoral stump of the ACL. The 2 sutures were then thread through a prebored tunnel in the tibia, where they were fixed extracortically over a second button with the knee in maximum extension (30°). A Kessler stitch using a No. 1 Vicryl suture was placed in the distal tibial stump of the ACL, and the remaining suture coming from the femoral button was knotted to it ( Figure 1 , ''Bioenhanced ACL repair'' column). 13 In the Blood group, 3 mL of autologous blood was drawn from the left femoral vein without addition of anticoagulant and was immediately used to saturate the scaffold ( Figure 1A ). In group ADSC, 3 3 10 6 ADSCs and in group PBSC, 3 3 10 6 PBSCs were mixed with 3 mL of autologous blood, drawn from the left femoral vein without addition of anticoagulant, before saturation of the scaffold with the cell-blood mixture (Figure 1 , C and E, respectively). After the addition of the blood to the scaffold, all animals were kept under anesthesia for 60 minutes to minimize joint movement until coagulation of the blood within the scaffold was completed. 48 After surgery, all animals were housed for 4 weeks in group pens and were then shipped to a farm (Coyote Consulting Corp). At 15 weeks after surgery, the animals were euthanized with pentobarbital, the limbs were harvested, and the knees were frozen at -20°C until mechanical testing. Euthanasia at 15 weeks was performed based on the results of a previous study which showed that minimum strength occurs between 6 and 9 weeks after bioenhanced ACL repair and that 15 weeks is a time point at which tissue maturation and generation of biomechanical strength are increasing. 22 
Biomechanical Testing
Biomechanical testing was performed as previously described. 15 A servohydraulic load frame with custom fixtures (MTS Systems Corp) was used to perform the biomechanical testing procedures (ie, AP knee laxity and the ligament structural properties). 15 During specimen testing, all investigators were blinded to the treatment group. The AP laxity of the knee and the structural properties of the ligaments were analyzed. 16 Briefly, AP laxity testing was done at 30°, 60°, and 90°of knee flexion by applying fully reversed, sinusoidal anterior posterior-directed shear loads of 640 N at 0.0833 Hz for 12 cycles as previously described. 26 The AP laxity tests were performed with axial rotation locked in a neutral position, while varus-valgus angulation and the coronal plane translations were left unconstrained. After AP laxity testing, the capsule, collateral ligaments, menisci, and posterior cruciate ligament were resected and specimen was placed in the tensile test fixtures. The femur was lowered until the load across the joint surface was 15 N of compression. The ACL was then stretched at a rate of 20 mm/min while the loaddisplacement data were recorded at 100 Hz. 24 Yield failure load, maximum failure load, and linear stiffness were determined from the load-displacement data.
Histology
After biomechanical testing, the repaired ACL was dissected free from the tibial and femoral insertion site and fixed in neutral buffered formalin. The ACL tissue was dehydrated and embedded in paraffin, and sagittal sections were stained with hematoxylin and eosin (H&E), a-smooth muscle actin (SMA), or YFP antibodies. 22 The slides were analyzed by an examiner blinded to the specimen number and treatment groups. Analysis was performed by use of bright-field microscopy for 5 regions of the ligament: the region 1 mm away from the femoral insertion site, the region 1 mm away from the tibial insertion site, and 3 regions in between those 2 regions, with the exclusion of the zone deformed by the biomechanical testing. The synovium was excluded from the analysis.
Advanced Ligament Maturity Index
A mixed qualitative/quantitative analysis using the Ligament Maturity Index (LMI) ( Table 1 ) was performed. The LMI is composed of 3 subscores determining cellular, collagen, and vascular organization. The cellular subscore assesses the presence of inflammatory cells, nuclear aspect ratio, and orientation of the fibroblasts relative to the collagen fibers, as well as fibroblast cell density (determined for individual visual fields of H&E-stained slides at 3400 magnification). The fibroblast cell density was determined at high magnification on H&E slides for individual visual fields. For this task, H&E is superior to SMA because the cell and cell core morphologic features are easily detectable (red cytoplasm, blue cell core); based on the cell core morphologic characteristics, fibroblasts are distinguishable from inflammatory cells because they are predominantly fusiform with elongated nuclei oriented along the length of the ligament. No inflammatory cells were detected in the specimens. The collagen subscore evaluates crimp appearance and collagen bundle orientation (determined for individual visual fields of H&E-stained slides at 340 magnification using polarized light). The vascular subscore determines orientation of blood vessels relative to the collagen fibers and the maturity as well as density of blood vessels (determined for individual visual fields of SMAstained slides at 3100 magnification). A maximum combined score of 26 was given to a healthy ligament. 39 
Statistical Methods
The sample size for this study was selected according to an a priori power calculation that used data from earlier studies 21, 22, 31, 48 to detect a 20% difference in yield load, maximum failure load, and linear stiffness between treatment groups with a standard deviation of 10% and an a (P value) of 5% with a minimum power of 95%.
General estimating equations were used to model the biomechanical parameters as a function of limb within animal and treatment condition. The within-subject error was modeled as correlated with a heterogeneous compound symmetry variance-covariance matrix structure, grouped blockdiagonal by treatment condition. This permitted different variances to be modeled in surgical and contralateral control limbs along with the within-subject covariance and allowed for groups to have different sets of values within this structure. The biomechanical parameters were modeled as either Gaussian (AP laxity) or log-normally (yield load, maximum failure load, linear stiffness) distributed, based on visual inspection of the distribution of each model's Pearson residuals. The maximum-likelihood estimators of the models were adjusted for any model misspecification by use of sandwich estimation. Mean differences with 95% CIs were expressed as absolute (Gaussian) or fold (backtransformed log-normal) for dissemination. A priori comparisons were made between affected and contralateral limbs within each treatment condition, and the magnitudes of these differences were compared between the treatment conditions. Differences between treatment groups in cell and vessel densities, LMI score and LMI subscores, and cell and vessel densities were assessed with 1-way analysis of variance (ANOVA). Bonferroni correction was used for multiple comparisons. An adjusted alpha value of 5% was considered significant. All data are presented as geometrical mean with a 95% CI.
RESULTS
Animal Welfare
All animals recuperated well after surgery. No wound infection, signs of local inflammation, or general sickness of the animals was seen during the 15-week period.
Scaffold Pore Size
The mean scaffold pore size was 208 6 68 mm.
Knee Biomechanics
The mean structural properties for the surgical and control knees and the mean normalized structural properties (relative to the contralateral leg) after 15 weeks of healing are presented in Figure 2 . Statistically significant lower biomechanical properties were detected between the intact contralateral control knees and 3 treatment groups (Blood, ADSC, PBSC) (P adj \ .05 for all comparisons between intact and treatment groups).
Normalized values of yield load, maximum failure load, and linear stiffness were calculated by division of treatment by intact side from each individual animal. Comparison of the means of normalized yield load, maximum load, and linear stiffness did not yield a statistically significant difference between the treatment groups (P adj . .999 for yield load, .104 . P adj . .972 for maximum failure load, P adj . .999 for linear stiffness) (Figure 2 , A-C).
Normalized values of AP laxity at 30°, 60°, and 90°were calculated by subtraction of treatment from intact side from each individual animal. Comparison of the means of normalized AP laxity at 30°, 60°, and 90°showed a statistically Vol. 43, No. 2, 2015 Stem Cell Addition to Bioenhanced ACL Repair 325 significant difference in AP laxity only at 30°between the Blood and PBSC groups (P adj \ .05) ( Figure 2D ). Treatment groups were not significantly different in AP laxity at 60°or 90°(P adj . .999 AP laxity at 60°, .529 \ P adj \ .737 for AP laxity at 90°) ( Figure 2 , E and F).
Histology
The repaired ligaments in all groups had an increased number of cells per visual field, collagen bundles that were smaller and less organized, collagen crimp with a higher crimp length and lower crimp height, and more vessels per visual field when compared with the intact ligaments ( Figure 3 ).
Ligament Maturity Index
The intact samples yielded a mean of 25.5 6 0.3 of 26 possible points for the combination of cellularity, collagen, and vessel LMI subscores. The repaired ligaments yielded statistically significant lower mean LMI values (15.4-17.5 points) than did the intact ACLs (P adj \ .001) ( Figure  4A ). Mean LMI scores did not differ significantly between the treatment groups (373 \ P adj .999) ( Figure 4A ). Cellularity. Cell subscores were statistically significantly higher in the intact group than in the treatment groups but were not different between the treatment groups themselves (P adj \ .001 and .540 \ P adj .999, respectively) (Figure 4A) . No inflammatory cells were detected in either intact or treatment groups. Fibroblast cell and nuclear morphologic characteristics in the intact ACLs were predominantly fusiform with elongated nuclei oriented along the length of the ligament. In all treatment groups, there were more areas containing cells with round-shaped nuclei and lower levels of fibroblast cell alignment than were present in the intact ligament (Figure 3 , ''H&E(4003)'' column).
Fibroblast cell density was significantly increased in the treated ACLs when compared with the intact ACLs. Fibroblast cell density did not differ significantly between the treatment groups (P adj \ .001 and P adj . .999, respectively) (Figure 3 , ''H&E(4003)'' column, and Figure 4B ). Mean fibroblast cell density in the intact ACLs was 394 cells/mm 2 , whereas the mean cell density in the treatment groups ranged from 1129 to 1273 cells/mm 2 .
Collagen Organization. At 15 weeks, LMI collagen subscores were statistically significantly higher in the intact group than in the treatment groups but were not different between the treatment groups themselves (P adj \ .001 and .542 \ P adj .999, respectively) ( Figure 4A ). Collagen bundles were generally smaller in the treatment groups than in the intact ACLs (Figure 3 , ''H&E (2003)'' column). However, in both the intact and treated ligaments, these bundles were predominantly aligned with the long axis of the ligaments. There were scattered areas of crimped fibers in the treated ligaments, and in those areas the crimp was organized longitudinally. However, this appearance was not uniform as seen in the intact ligaments ( Figure  3 Vascularity. The vessel subscore of the treatment groups at 15 weeks was significantly lower than in the intact ACLs, but no statistically significant difference was detected between the treatment groups themselves (P adj \ .001 and .987 \ P adj .999, respectively) ( Figure  4A ). Most of the vessels in the treated ligaments had aligned with the collagen bundles and the long axis of the ligament. In all treated ligaments, mature arterioles that had multiple layers of SMA-positive smooth muscle cells (compared with capillaries lined by a single endothelial cell layer) were detectable (Figure 3 , ''SMA(1003)'' column).
The vessel density was higher in the repaired ligaments than in the intact ligaments but did not differ significantly between the treatment groups themselves (P adj \ .001 and .642 \ P adj .999, respectively) ( Figure 3 , ''SMA(1003)'' column, and Figure 4C ).
YFP-Labeled Cells
Control in vitro cell culture of YFP-labeled ADSCs and PBSCs showed positive fluorescence at 15 weeks. Neither dark field fluorescence microscopy nor immunohistochemical staining against YFP of formalin fixed ACL sections showed cells expressing YFP.
DISCUSSION
In this study, we hypothesized that enrichment of the whole blood used in a bioenhanced repair technique with stem cells would result in additional improvements in healing of the injured ACL. However, after 15 weeks of healing, we found no evidence to support our hypothesis. Neither ADSCs nor PBSCs led to a statistically significant improvement of the bioenhanced ACL repair in the mean normalized yield and maximum failure loads, linear stiffness, or AP laxity. In addition, we were unable to detect any significant differences in cellular and vascular densities or ligament maturity scores when either type of MSCs was added.
The biomechanical results of the present study are in conformance with the previous studies of bioenhanced ACL repair. 27, 31, 48 Yield and maximum failure load in this study averaged 25% and 23% of the intact ACL values, while they previously had been measured at 21% to 26% and 22% to 27% at 15 weeks after bioenhanced ACL repair, respectively. Linear stiffness values of 32% of the intact ACL values in this study were comparable with earlier results that averaged between 20% and 33%. 28, 31, 40 The . N Statistically significant difference between intact and treatment groups (P \ .05). Blood, bioenhanced ACL repair; ADSC, bioenhanced ACL repair with addition of adipose tissue-derived stem cells; PBSC, bioenhanced ACL repair with addition of peripheral blood mononuclear cell-derived stem cells.
linear stiffness results are encouraging as this is the parameter that tissue engineers attempt to replicate as ligaments and tendons routinely operate in the range that is less than 10% of the failure load when patients perform activities of daily living. 6 We were not able to detect any fluorescent cells in the bioenhanced ACL repair groups treated with ADSCs or PBSCs. While the MSCs maintained for 15 weeks in vitro cultures could be visualized, suggesting that the cells are able to continue to express the fluorescent protein for 15 weeks, no fluorescent cells were detected in the ACL tissue. Possible reasons in the present study include the process of freeze-thaw or histologic processing that may have rendered the YFP label inactive. However this finding could also indicate that the ADSCs and PBMCs did not survive the entire 15 weeks after transplantation into the knee. This would be consistent with prior reports using MSCs in the knee joint, where few, if any, cells are found in the repair sites of cartilage or ligament 3 weeks after implantation. 46 It would also be consistent with studies in multiple other tissues, where MSC cell survival after transplant is typically less than 4 weeks in liver, 52 brain, 9 and heart. 38, 44, 47 However, unlike these prior studies that demonstrated some functional improvements after MSC injection, even with the observed early cell death, in this study we found no functional contribution to the biomechanical healing with the addition of ADSCs or PBSCs to the whole blood in the scaffold. This suggests that the trophic effects previously observed in other studies of MSCs may also be provided by the cells present in whole blood (platelets, white blood cells, red blood cells).
There are several limitations to this study. This study was performed in nonhuman knees. We chose the porcine model because its knee anatomy and size and characteristics of blood are very close to those of a human. The porcine model also exhibits similar biomechanical function and ACL dependence. 5 However, it is a quadruped rather than a biped. Another limitation was the single freezethaw cycle the knee specimens experienced, which could have potentially influenced the biomechanical outcomes. To minimize variability due to this treatment between the groups, the freeze-thaw protocol was consistent for all specimens.
There are multiple possible reasons for the observed failure of the implanted MSCs to affect the functional outcome of bioenhanced ACL repair in this model, including early MSC death, the MSCs actively migrating out of the scaffold, or a harmful effect of the autologous whole blood on the autologous MSCs in vivo. Regarding the possible harmful effect of whole blood, the peripheral blood MSCs are derived from whole blood. Therefore, PBMCs are unlikely to be adversely effected by replacing them into their native environment. In addition, ADSCs are commonly administered via intravenous injection in experimental models with good functional effect in other organs. 10, 41, 45 This intravenous injection would be directly into autologous whole blood. Based on the results of these prior reports, a harmful effect of autologous whole blood on the MSCs is less likely. Another possible cause is that the trophic factors released by MSCs in the wound site, which are thought to be the main mechanism by which MSCs improve functional outcomes, 29 are similar to those released from the platelets in the whole blood after collagen activation. The trophic factors thought to be released by MSCs after implantation include vascular endothelial growth factor (VEGF), 43 EGF, 28 and FGF-2, 28 all factors known to be released from platelets after activation with collagen. 19, 37, 50 Activated platelets also release hepatocyte growth factor (HGF), insulin-like growth factor (IGF)-1, platelet-derived growth factor (PDGF)-AB, PDGF-BB, and transforming growth factor (TGF)-b1, which are also thought to be important in wound healing. 12 Thus, it is possible that the observed failure of the implanted MSCs to affect the functional outcome of bioenhanced ACL repair in this model may have occurred because the trophic effects of the platelets in the whole blood preparation camouflaged the trophic effects of the added MSCs.
Another limitation of this study was that it did not use protocols approved by the US Food and Drug Administration (FDA) for cell harvest and culture. Thus, use of these sources of stem cells would require additional study and development of appropriate manufacturing protocols before proceeding to a clinical study.
Also limiting in the current study was the use of lentiviral vectors to label the cells. Current standard transduction methods using lentiviral vectors are known to inhibit MSC proliferation rate and potentially the differentiation potential of the transduced cells. However, we have previously demonstrated the fibroblast-like differentiation capabilities and proliferation capacity of both the ADSCs and PBMCs after lentiviral transduction in this porcine model. 40 In this study, the histological analyses were performed after biomechanical testing had been conducted. During testing for yield and maximum load, the collagen crimp will first flatten reversibly. This phase is followed by inelastic deformation. 18 In this study, the irreversible changes in the collagen were kept minimal by use of a servohydraulic load frame. Thus, testing was performed in a very controlled manner, stopping right after the drop in load occurred to minimize gross tissue damage. Furthermore, most ligaments failed in the midsubstance, with a visible focal defect. The region of failure was excluded from the histologic analysis, because the evaluation of crimp length in this passage, and thus the collagen subscore, could have been altered. Moreover, all specimens were tested identically, making it likely that any changes in the collagen subscores would have occurred uniformly.
Whole blood as a biologic adjunct for soft tissue healing has only recently received attention. It has been previously appreciated that platelets are an important growth factor delivery system. 19 Whole blood contains leukocytes, lymphocytes, and macrophages, which are involved in the signaling and regulation of the wound healing. 17 Whole blood also contains red blood cells, which have been demonstrated to stimulate collagen production by ACL fibroblasts, 20 possibly because of their ability to serve as an oxygen source before sufficient blood supply is established within the wound site. 20 And as shown before, whole blood contains stem cells that have the potential to differentiate into the fibroblast cell line. 7, 8, 23, 40 This study compares the outcomes of MSCs with whole blood rather than an empty carrier. The use of whole blood as a control is important, as whole blood is inexpensive, can be ''harvested'' at the time of surgery, and does not need to be cultured and then reimplanted in a second procedure. Thus, whole blood represents a practical biologic adjunct to ligament repair and could potentially be used as a baseline for comparisons of other adjuncts before clinical use of more complicated constructs is contemplated. The results of this study support the biologic utility of whole blood in wound healing and suggest that the more intense and costly procedures of stem cell harvest, culture, and reimplantation may not be effective in further enhancing ligament repair.
CONCLUSION
The data suggest that in this study there is little functional benefit gained with the enrichment of whole blood with MSCs from either the retropatellar fat pad or the peripheral blood for bioenhanced ACL repair. The use of whole blood alone was equally effective in supporting biomechanical healing of the ACL in the current experimental setting.
